
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
In this video Akeel Williams, VP of Strategy and Operations, Manufacturer Solutions, explains how GoodRx uses data to continuously improve its platform for patients and providers.





